These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17728212)

  • 1. Is a screening interval of every 4 years for prostate cancer acceptable?
    Crawford ED
    J Natl Cancer Inst; 2007 Sep; 99(17):1279-80. PubMed ID: 17728212
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Is a screening interval of every 4 years for prostate cancer acceptable?
    Roobol MJ; Schröder FH
    J Natl Cancer Inst; 2008 Feb; 100(3):222; author reply 223-4. PubMed ID: 18230797
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate specific antigen and screening for early prostate cancer.
    Davidson P
    N Z Med J; 2001 Apr; 114(1129):150. PubMed ID: 11400919
    [No Abstract]   [Full Text] [Related]  

  • 4. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA and prostate cancer screening: the challenge of the new millennium.
    Bjartell A
    Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer screening.
    Catalona WJ
    BJU Int; 2004 Nov; 94(7):964-6. PubMed ID: 15541107
    [No Abstract]   [Full Text] [Related]  

  • 7. Screening for prostate cancer: recommendations and rationale.
    Berg AO;
    Am J Nurs; 2003 Mar; 103(3):107-10; discussion 111. PubMed ID: 12626949
    [No Abstract]   [Full Text] [Related]  

  • 8. Application of prostate-specific antigen in prostate cancer.
    Liang SL
    MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Terris MK
    Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective.
    Hayes JH; Barry MJ; Kantoff PW; Stahl JE
    BJU Int; 2007 Sep; 100(3):486-8. PubMed ID: 17669139
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate-specific antigen and prostate cancer prognosis.
    Church TR
    J Natl Cancer Inst; 2006 Nov; 98(21):1509-10. PubMed ID: 17077347
    [No Abstract]   [Full Text] [Related]  

  • 12. Is the PSA test useless?
    Kirby R; Moul JW
    Prostate Cancer Prostatic Dis; 2004; 7(4):271-2. PubMed ID: 15592438
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate cancer: current evidence weighs against population screening.
    Boyle P; Brawley OW
    CA Cancer J Clin; 2009; 59(4):220-4. PubMed ID: 19564244
    [No Abstract]   [Full Text] [Related]  

  • 14. Weighing the benefits and downsides of prostate-specific antigen screening.
    Pignone M
    Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening for prostate cancer.
    Malone P
    Ann R Coll Surg Engl; 2005 Mar; 87(2):88-9. PubMed ID: 16790126
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73.
    Kvåle R; Hernes E; Bray F
    Eur Urol; 2009 May; 55(5):e88-9; author reply e90-1. PubMed ID: 19062155
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 18. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate cancer screening "reloaded".
    Gomella LG
    Can J Urol; 2010 Apr; 17(2):5057. PubMed ID: 20398441
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Yuen JS
    J Urol; 2004 Mar; 171(3):1246. PubMed ID: 14767320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.